CTI BioPharma

YTD

ALL

Why Robinhood?

You can watch CTI BioPharma and buy or sell other stocks, ETFs, and their options commission-free!

About CTIC

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers.

CEO

Adam R. Craig, MD, PhD

CEOAdam R. Craig, MD, PhD

Employees

—

Employees—

Headquarters

Seattle, Washington

HeadquartersSeattle, Washington

Founded

1991

Founded1991

Employees

—

Employees—

CTIC Key Statistics

Market cap

1.20B

Market cap1.20B

Price-Earnings ratio

-15.78

Price-Earnings ratio-15.78

Dividend yield

—

Dividend yield—

Average volume

4.57M

Average volume4.57M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$9.10

52 Week high$9.10

52 Week low

$4.01

52 Week low$4.01